Skip to main content
Karamjeet Sandhu, MD, Hematology, Duarte, CA

Karamjeet Singh Sandhu MD

Hematologic Oncology, Hemophilia & Bleeding Disorder, Myeloproliferative Disorder Hematology-Oncology


Assistant Professor

Join to View Full Profile
  • 1500 Duarte RdDept of Hematology Hematopoietic Cell TransplantationDuarte, CA 91010

  • Phone+1 626-256-4673

  • Fax+1 626-301-8116

Dr. Sandhu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Minnesota
    University of MinnesotaFellowship, Hematology and Medical Oncology, 2012 - 2015
  • Hennepin Healthcare
    Hennepin HealthcareResidency, Internal Medicine, 2009 - 2012
  • Tver State Medical Academy
    Tver State Medical AcademyClass of 2000

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - 2026
  • MN State Medical License
    MN State Medical License 2014 - 2016

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
    Karamjeet S. Sandhu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
    Karamjeet S. Sandhu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • City of Hope Doctors Present New Research on Cancer Immunotherapies
    City of Hope Doctors Present New Research on Cancer ImmunotherapiesNovember 4th, 2021
  • Initial Patient Dosed in Phase 2a Clinical Trial Evaluating First-in-Class Human Milk-Based Therapy in Patients Undergoing Stem Cell Transplantation for Blood Cancers
    Initial Patient Dosed in Phase 2a Clinical Trial Evaluating First-in-Class Human Milk-Based Therapy in Patients Undergoing Stem Cell Transplantation for Blood CancersNovember 15th, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: